Lobe Sciences Ltd. Announces Strategic Moves to Strengthen Financial Position and Market Presence

VANCOUVER, BC — Lobe Sciences Ltd., a Canadian biotechnology company specializing in the development of novel drugs for neurological disorders, has recently announced two significant strategic initiatives aimed at bolstering its financial position and enhancing its market presence. These developments were disclosed on July 29, 2025, and include a private placement and the engagement of a capital markets advisory firm.

Private Placement for General Corporate Purposes

Lobe Sciences Ltd. has announced a non-brokered private placement (the “Offering”) of up to 8,535,625 common shares at a price of $0.04 per share, aiming to raise gross proceeds of up to $341,425 CAD. This move is intended for general corporate purposes, providing the company with additional capital to support its ongoing operations and development programs. The company, listed on the Canadian National Stock Exchange, has a market capitalization of 13,570,000 CAD and a close price of 0.065 CAD as of July 24, 2025. The net proceeds from this offering will be instrumental in advancing Lobe Sciences’ research and development efforts, particularly in its focus areas of Alzheimer’s disease and Huntington’s disease.

Engagement with ArcStone Securities for Strategic Advisory

In a parallel strategic move, Lobe Sciences Ltd. has engaged ArcStone Securities and Investments Corp., a capital markets advisory firm, to provide comprehensive advisory services. This partnership is designed to enhance Lobe Sciences’ market visibility and institutional investor engagement across North American markets. Under the terms of the agreement, ArcStone will assist with capital markets planning, institutional investor engagement, and strategic positioning. The collaboration is expected to support Lobe Sciences’ development programs and strengthen its presence in both Canadian and U.S. financial markets.

These strategic initiatives reflect Lobe Sciences Ltd.’s commitment to advancing its mission of developing therapeutics for rare and underserved diseases. By securing additional capital and leveraging expert advisory services, the company aims to accelerate its research and development efforts and enhance its competitive position in the biopharmaceutical industry.